Literature DB >> 16568084

The SRC family kinase LYN redirects B cell receptor signaling in human SLP65-deficient B cell lymphoma cells.

M Sprangers1, N Feldhahn, S Herzog, M-L Hansmann, M Reppel, J Hescheler, H Jumaa, R Siebert, M Müschen.   

Abstract

SLP65 represents a critical component in (pre-) B cell receptor signal transduction but is compromised in a subset of pre-B cell-derived acute lymphoblastic leukemia. Based on these findings, we investigated (i.) whether SLP65-deficiency also occurs in mature B cell-derived lymphoma and (ii.) whether SLP65-deficient B cell lymphoma cells use an alternative B cell receptor signaling pathway in the absence of SLP65. Indeed, expression of SLP65 protein was also missing in a fraction of B cell lymphoma cases. While SLP65 is essential for B cell receptor-induced Ca2+ mobilization in normal B cells, B cell receptor engagement in SLP65-deficient as compared to SLP65-reconstituted B cell lymphoma cells resulted in an accelerated yet shortlived Ca2+-signal. B cell receptor engagement of SLP65-deficient lymphoma cells involves SRC kinase activation, which is critical for B cell receptor-dependent Ca2+-mobilisation in the absence but not in the presence of SLP65. As shown by RNA interference, the SRC kinase LYN is required for B cell receptor-induced Ca2+ release in SLP65-deficient B cell lymphoma cells but dispensable after SLP65-reconstitution. B cell receptor engagement in SLP65-deficient B cell lymphoma cells also resulted in tyrosine-phosphorylation of the proliferation- and survival-related MAPK1 and STAT5 molecules, which was sensitive to silencing of the SRC kinase LYN. Inhibition of SRC kinase activity resulted in growth arrest and cell death specifically in SLP65-deficient lymphoma cells. These findings indicate that LYN can short-circuit conventional B cell receptor signaling in SLP65-deficient B cell lymphoma cells and thereby promote activation of survival and proliferation-related molecules.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16568084     DOI: 10.1038/sj.onc.1209510

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  3 in total

1.  Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma.

Authors:  Jayadev M Umakanthan; Javeed Iqbal; Connie L Batlevi; Alyssa Bouska; Lynette M Smith; Valerie Shostrom; Heather Nutsch; Basem M William; R Gregory Bociek; Matthew Lunning; Philip Bierman; Anas Younes; James O Armitage; Julie M Vose
Journal:  Br J Haematol       Date:  2018-12-05       Impact factor: 6.998

2.  BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3.

Authors:  Joji Nakayama; Mutsumi Yamamoto; Katsuhiko Hayashi; Hitoshi Satoh; Kenji Bundo; Masato Kubo; Ryo Goitsuka; Michael A Farrar; Daisuke Kitamura
Journal:  Blood       Date:  2008-12-01       Impact factor: 22.113

3.  Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function.

Authors:  Daniel Trageser; Ilaria Iacobucci; Rahul Nahar; Cihangir Duy; Gregor von Levetzow; Lars Klemm; Eugene Park; Wolfgang Schuh; Tanja Gruber; Sebastian Herzog; Yong-mi Kim; Wolf-Karsten Hofmann; Aihong Li; Clelia Tiziana Storlazzi; Hans-Martin Jäck; John Groffen; Giovanni Martinelli; Nora Heisterkamp; Hassan Jumaa; Markus Müschen
Journal:  J Exp Med       Date:  2009-07-20       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.